Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development

Core Insights - Galapagos NV has announced changes to its Board of Directors to enhance governance and align with its strategic direction focused on business development and novel medicines [1][10] Board Composition Changes - Dr. Neil Johnston has been appointed as a Non-Executive Independent Director, and Devang Bhuva as a Non-Executive Non-Independent Director, both effective November 1, 2025 [2] - An additional Non-Executive Independent Director is expected to be appointed soon to ensure a balanced and diversified Board [2] Departures from the Board - Non-Executive Independent Directors Dr. Elisabeth Svanberg and Dr. Susanne Schaffert, along with Non-Executive Non-Independent Director Andrew Dickinson, will step down from their positions effective November 1, 2025 [3] Leadership Statements - Jérôme Contamine, Chair of the Board, expressed confidence that the new directors' financial leadership and strategic transaction experience will be crucial for the company's transformation and value creation [4] - CEO Henry Gosebruch emphasized the importance of these changes for steering the company towards sustainable growth and enhancing stakeholder value [4] Director Backgrounds - Dr. Neil Johnston has extensive experience in biopharma, previously serving as Executive Chair at Yellowstone Biosciences and holding senior roles at Novartis [5] - Devang Bhuva has a strong background in corporate development and investment banking, currently serving as Senior Vice President at Gilead [6]